Prostate Cancer Screening as Effective as Breast Cancer Screening, Study Finds

Prostate Cancer Screening as Effective as Breast Cancer Screening, Study Finds

March 15, 2026 Nkechi Okonkwo- Health Editor Health

New research presented at the European Association of Urology Congress (EAU26) in London suggests that prostate cancer screening can be as effective as breast cancer screening in identifying significant cancers, reducing mortality, and minimizing unnecessary harms. The findings, accepted for publication in European Urology, are prompting a re-evaluation of why prostate cancer screening has historically lagged behind breast cancer screening despite being the most commonly diagnosed cancer in European men.

Comparing Screening Approaches

For decades, organized breast cancer screening programs have been a standard practice across Europe, utilizing mammography to detect potential cancers early. Prostate cancer screening, yet, has faced resistance, largely due to concerns about the reliability of the prostate-specific antigen (PSA) blood test and the potential for overdiagnosis – identifying cancers that would never have caused harm during a man’s lifetime – and subsequent overtreatment. Despite these concerns, many men still seek prostate cancer screening through ‘opportunistic’ routes, often self-referring to their doctors.

Recent long-term data from several European prostate cancer screening trials have demonstrated a reduction in deaths from prostate cancer as reported by the European Association of Urology. This risk reduction is now comparable to that observed in established breast cancer screening programs. The new analysis, conducted by researchers at the German Cancer Research Centre in Heidelberg, Germany, directly compared the two screening methods.

The PROBASE Trial and German Breast Cancer Screening Data

The researchers analyzed data from the PROBASE prostate cancer screening trial, which involved nearly 40,000 men aged 45 or 50 who underwent initial PSA testing. This data was then compared to information from over 2.8 million women aged 50-69 who participated in Germany’s organized breast cancer screening program, receiving mammograms. The comparison focused on the effectiveness of the diagnostic tests and the levels of overdiagnosis.

The analysis revealed some key differences and similarities:

  • False Positives: PSA testing followed by MRI scans resulted in a higher rate of false positives (37-42%) compared to mammography (10%). A false positive indicates the test suggests cancer when none is present.
  • Biopsy Referrals: A similar proportion of men (0.8-2.4%) and women (1.1%) were referred for further investigation (biopsy). Importantly, men in the PROBASE trial underwent ‘risk stratification’ – a process of assessing the likelihood of significant cancer before referral – which likely contributed to this similarity.
  • Significant Cancer Detection: Biopsies were significantly more likely to identify aggressive cancers in prostate screening (50-68%) than in breast screening (10%), suggesting fewer unnecessary biopsies among men.
  • Cancer Identification Rates: The overall percentage of invasive cancers identified through both prostate and breast cancer screening was comparable (60-74% vs 73%).
  • Non-Aggressive Cancers: Prostate cancer screening was more likely to detect non-aggressive cancers (26-31%) than breast cancer screening (22%). However, the researchers note that ‘active surveillance’ – a strategy of closely monitoring low-risk cancers rather than immediately treating them – is a well-established option for managing these cases, minimizing the risk of overtreatment.

What So for Prostate Cancer Screening

Dr. Sigrid Carlsson, lead author of the research and head of Clinical Epidemiology of Early Cancer Detection at the German Cancer Research Centre, emphasized that while a direct comparison isn’t yet possible without a population-based prostate cancer screening program, the trial data suggests that extending screening to the wider population would likely yield outcomes similar to those seen in breast cancer screening. As reported by Mirage News, Dr. Carlsson also highlighted the need to assess the cost-effectiveness of widespread prostate cancer screening compared to the current opportunistic approach.

The study acknowledges that the comparison is not perfect, as it contrasts a trial setting with an established population-based screening program. However, the findings challenge the long-held rationale for rejecting prostate cancer screening while simultaneously endorsing breast cancer screening.

The Role of MRI and Risk Stratification

The increased use of MRI scans in prostate cancer screening, coupled with risk stratification techniques, appears to be playing a crucial role in improving the accuracy of diagnosis and reducing unnecessary biopsies. Risk stratification involves considering factors such as PSA levels, MRI findings, and patient characteristics to determine the likelihood of aggressive cancer. This allows clinicians to focus biopsies on men who are most likely to benefit from treatment.

Tobias Nordström, a clinical urologist and Associate Professor at the Karolinska Institute in Sweden, and a member of the EAU Scientific Congress Office, noted that prostate cancer screening can learn valuable lessons from the established breast cancer screening model. He cautioned that the results should be interpreted with some caution, but acknowledged that the overall similarities in outcomes between breast and prostate cancer screening indicate progress towards a more effective and beneficial screening approach.

Health-Related Quality of Life and Screening Anxiety

Beyond the clinical effectiveness of screening, research presented at the EAU26 also explored the impact of prostate cancer screening on men’s health-related quality of life and anxiety levels. According to UroToday.com, Dr. Shuang Hao presented findings indicating that screening can induce anxiety in some men, highlighting the importance of providing adequate support and information throughout the screening process.

PSMA PET/CT: A Potential Diagnostic Advance

Further advancements in diagnostic technology were also presented at the EAU26. Research suggests that PSMA PET/CT scans – a molecular imaging technique – may transform prostate cancer diagnosis and reduce the need for biopsies. Health and Pharma reports that PSMA PET/CT scans can more accurately identify the location and extent of prostate cancer, potentially leading to more targeted biopsies and improved treatment decisions.

Looking Ahead

The evolving landscape of prostate cancer screening necessitates ongoing evaluation and refinement. Further research is needed to determine the optimal screening strategies, including the appropriate age to begin screening, the frequency of screening, and the role of emerging technologies like PSMA PET/CT. Cost-effectiveness analyses will also be crucial in informing policy decisions and ensuring equitable access to screening for all men at risk. The goal is to strike a balance between early detection and minimizing the harms associated with overdiagnosis and overtreatment, ensuring that prostate cancer screening truly benefits the men it aims to protect.